Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E78.50 EPS (ttm)3.78 Insider Own1.50% Shs Outstand99.93M Perf Week1.06%
Market Cap29.65B Forward P/E43.35 EPS next Y6.85 Insider Trans-3.32% Shs Float75.46M Perf Month-9.90%
Income424.40M PEG2.71 EPS next Q0.94 Inst Own78.50% Short Float5.17% Perf Quarter2.16%
Sales2.10B P/S14.09 EPS this Y-43.60% Inst Trans-0.10% Short Ratio3.24 Perf Half Y-3.55%
Book/sh19.75 P/B15.02 EPS next Y57.43% ROA16.60% Target Price344.74 Perf Year43.59%
Cash/sh6.94 P/C42.73 EPS next 5Y29.00% ROE25.90% 52W Range203.70 - 352.49 Perf YTD7.81%
Dividend- P/FCF69.40 EPS past 5Y42.20% ROI19.20% 52W High-15.82% Beta1.01
Dividend %- Quick Ratio5.80 Sales past 5Y54.60% Gross Margin91.00% 52W Low45.68% ATR13.27
Employees2340 Current Ratio6.00 Sales Q/Q47.20% Oper. Margin36.10% RSI (14)45.62 Volatility4.19% 4.63%
OptionableYes Debt/Eq0.26 EPS Q/Q-79.40% Profit Margin20.20% Rel Volume0.50 Prev Close300.14
ShortableYes LT Debt/Eq0.26 EarningsMay 08 BMO Payout0.00% Avg Volume1.20M Price296.74
Recom2.20 SMA20-1.30% SMA50-6.34% SMA2003.50% Volume606,501 Change-1.13%
16-Apr-14Initiated Canaccord Genuity Buy $350
13-Feb-14Downgrade Oppenheimer Outperform → Perform $310 → $325
30-Sep-13Reiterated Oppenheimer Outperform $300 → $310
22-Aug-13Initiated Oppenheimer Outperform $300
17-May-13Initiated UBS Neutral $290
06-May-13Reiterated RBC Capital Mkts Outperform $270 → $286
06-May-13Reiterated Barclays Overweight $275 → $305
02-May-13Reiterated Barclays Overweight $194 → $275
28-Feb-13Initiated Barclays Overweight $194
21-Dec-12Reiterated RBC Capital Mkts Outperform $171 → $190
14-Feb-12Reiterated RBC Capital Mkts Outperform $83 → $130
10-Jan-12Upgrade Robert W. Baird Neutral → Outperform $56 → $81
05-Dec-11Reiterated Brean Murray Buy $78 → $67
28-Jul-11Upgrade RBC Capital Mkts Sector Perform → Outperform $70 → $70
09-May-11Reiterated Needham Buy $49 → $60
29-Apr-11Reiterated Barclays Capital Overweight $64 → $72
29-Apr-11Downgrade RBC Capital Mkts Outperform → Sector Perform $70 → $70
28-Apr-11Reiterated RBC Capital Mkts Outperform $48 → $70
28-Apr-11Reiterated Brean Murray Buy $67 → $78
27-Apr-11Reiterated Brean Murray Buy $57 → $67
17-Apr-14 06:00AM  Once a Notorious Short Seller, Martin Shkreli Now Sees a Future in Biotech at BusinessWeek
16-Apr-14 06:32PM  ModernGraham Annual Valuation Of Regeneron Pharmaceuticals at Seeking Alpha
02:21PM  [video] Bull case for Regeneron at CNBC
12:02PM  Yahoo rallies on revenue growth; Bank of America in red at MarketWatch
09:23AM  New Stock Coverage: Use (Don't Lose) Your Head in Regeneron at Minyanville
08:43AM  Will This Coverage Initiation Help Regeneron (REGN) Stock Today? at TheStreet
08:22AM  Coverage initiated on Regeneron Pharms by Canaccord Genuity Briefing.com
15-Apr-14 05:40PM  Bristol-Myers Seeks Approval for HIV Combo Drug Zacks
05:26PM  Health Care Stocks: Check Out This Low-Cost Market Beater at Motley Fool
04:20PM  Encouraging Results from Lexicon Candidate Zacks
04:15PM  FDA Nod for Merck's Grastek Zacks
03:30PM  Portola's Betrixaban Study Design Published Zacks
01:19PM  Another Earnings Beat from J&J, View Up Zacks
12:40PM  [video] Love biotech on correction: Trader at CNBC
12:37PM  [video] Top biotech analyst forecasts bottom at CNBC
09:05AM  Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend? at Motley Fool
06:49AM  Ambit Biosciences Slumps: AMBI Falls 13.0% in Session Zacks
14-Apr-14 10:00AM  The Cost to Treat Cholesterol Plummets, But Will It Last? at Motley Fool
11-Apr-14 09:30AM  Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014 PR Newswire
10-Apr-14 03:53PM  Is the robust IPO market affecting the broader indices? at TheStreet
09-Apr-14 05:16PM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online +6.92%
01:27PM  Intuitive Surgical slumps; Facebook extends rally at MarketWatch
12:27PM  [video] The biotech parade at CNBC
12:26PM  Regeneron Down 15% From 52-Week High: Buy? at Seeking Alpha
12:18PM  Midday movers: Apache, Hershey, Facebook & More at CNBC
12:12PM  Intuitive Surgical slumps; Facebook extends rally at MarketWatch
07-Apr-14 06:23PM  There's still value in biotech stocks: Citi pro at CNBC
05:43PM  [video] Biotech breakdown? at CNBC
05:25PM  Tweet of the Week: Big Biotech Dominates Industry Gains at Motley Fool
11:02AM  [$$] Biotech Bull-Run Versus Bubble at Barrons.com
04-Apr-14 09:08PM  Momentum names may see more pain Reuters
04:00PM  Robert A. Ingram Elected to Regeneron Board of Directors PR Newswire
03-Apr-14 04:00PM  Regeneron Announces Initiative for STEM Education in Hudson Valley PR Newswire
01:27PM  S&P 500 Edges Lower As Biotech Selling Weighs On Nasdaq at Investor's Business Daily
10:52AM  Will Growing PCSK9 Competition Hinder Regenerons Stock? at Wall St. Cheat Sheet
08:31AM  The Zacks Analyst Blog Highlights: Gilead, MannKind, Cubist, Regeneron and Medicines Co Zacks
02-Apr-14 01:02PM  3 Stocks Underperforming Today In The Drugs Industry at TheStreet
10:30AM  Encouraging Data on Sanofi/Regeneron's Alirocumab Zacks
09:46AM  Hot HFT debate may claim Virtu's IPO as victim at CNBC
09:43AM  Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update Zacks
01-Apr-14 02:31PM  Can This Drive Growth for Amarin Corporation plc? at Motley Fool
12:54PM  Health care stocks are outperforming; consider these picks from analyst Les Funtleyder Breakout
10:30AM  Insider Trading Alert - LQDT, REG And REGN Traded By Insiders at TheStreet
08:16AM  Sanofi and Regeneron report positive results from Phase 2 study with alirocumab theflyonthewall.com
08:00AM  Sanofi and Regeneron Report Positive Results With Alirocumab From Phase 2 Japanese Study PR Newswire
31-Mar-14 02:51PM  [video] Injectable cholesterol drugs to face challenges at CNBC
01:59PM  Amgen Stock Gets Bump Up On Cholesterol Drug Data at Investor's Business Daily
11:41AM  Amgen's Good News Bad News for Regeneron? at Barrons.com
09:00AM  Sanofi SA and Regeneron Pharmaceuticals Inc IR Thematic Conference Call on Alirocumab scheduled for 9:00 am ET today CCBN
08:49AM  Sanofi SA and Regeneron Pharmaceuticals Inc IR Thematic Conference Call on Alirocumab scheduled for 9:00 am ET today CCBN
28-Mar-14 06:43PM  Cramer's homework: Buy vaccine maker for 'spec'? at CNBC
02:36PM  Rebound Rally Losing More Steam; BitAuto Hangs Tough at Investor's Business Daily
01:03PM  3 Stocks Pushing The Health Care Sector Downward at TheStreet
11:00AM  Aegerion Pharmaceuticals Viability Threatened As Regulatory, Legal And Market Forces Close In at Seeking Alpha
27-Mar-14 06:41PM  New Cholesterol Fighters To Take Center Stage At ACC at Investor's Business Daily
07:32AM  Three Misplaced Assumptions That Could End The Biotech Boom at Forbes
07:32AM  Biotech Stocks: Seeing Rainbows, Missing The Rain at Forbes
02:00AM  Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session PR Newswire
26-Mar-14 02:39PM  US STOCKS-Wall St lower in volatile trading; tech, materials down Reuters
12:48PM  US STOCKS-Dow, S&P 500 rise as Ukraine tensions ebb; US data helps Reuters
10:34AM  US STOCKS-Wall Street gains on data, easing of Ukraine tensions Reuters
10:30AM  Stocks: Insiders Buy at Regeneron, Valeant, and MDC Partners at Minyanville
25-Mar-14 06:43PM  Cramer: Vicious trend could hit good stocks at CNBC
04:45PM  US STOCKS-Wall St rebounds; biotech shares snap losing streak Reuters
03:40PM  [video] IPO red flags at CNBC
03:08PM  US STOCKS-Wall St rebounds as biotech moves back to positive zone Reuters
01:32PM  [video] Warning signs from IPOs at CNBC
12:47PM  US STOCKS-Wall St cuts gains as tech stocks reverse course Reuters
12:38PM  [$$] Clinton Group Calls For Nutrisystem to Buy Back Stock at The Wall Street Journal
12:06PM  Review: An Android Phone Gets Even Better at The Wall Street Journal
11:37AM  [$$] Malaysia Airlines Insurers to Split Plane Cost at The Wall Street Journal
10:43AM  US STOCKS-Wall St rises, biotech stocks snap losing streak Reuters
24-Mar-14 06:32PM  Will This Stock Rule the Next Generation of Cholesterol Medicine? at Motley Fool
02:03PM  [video] Biotech could see more weakness: Pro at CNBC
01:50PM  $1,000 a pill? It's a U.S. problem, pro says at CNBC
10:32AM  JPMorgan Sees No Bubble, Hears No Bubble as Biotech Falls Again at Barrons.com
10:15AM  Insider Trading Alert - REGN, SZYM And SPW Traded By Insiders at TheStreet
10:04AM  Insider Trading Alert - REGN, SZYM And SPW Traded By Insiders at TheStreet
08:05AM  [video] What's working in biotech: CELG, ALXN & more at CNBC
22-Mar-14 11:02AM  Could Isis Threaten Regeneron and Novartis? at Motley Fool
21-Mar-14 01:02PM  [video] Biotech weighs on S&P at CNBC -5.45%
12:30PM  [video] US Democrats ask Gilead about pricing at CNBC
20-Mar-14 05:03PM  Do You Take Statins? If Not, You May Be Soon at Motley Fool
10:03AM  Why Pfizer Investors Should Watch Quark This Summer at Motley Fool
09:31AM  Can Regeneron Keep Churning Out Blockbusters? at Motley Fool
18-Mar-14 07:17PM  The Lesson of Allergan at TheStreet
08:48AM  Rivals race to develop new biotech asthma drugs Reuters
17-Mar-14 06:13PM  Netflix, Other Big Cap Growth Stocks Offer Buy Points at Investor's Business Daily
11:36AM  Amgen's PCSK9 Scores Against Genetic High Cholesterol at Investor's Business Daily
10:41AM  Jim Cramer's Mad Dash: HTZ REGN at TheStreet
10:33AM  Stocks: Three Insiders Sell at FireEye; Regeneron Sees a Purchase at Minyanville
10:23AM  Regeneron: There Won't Be a Better Opportunity to Buy, Citigroup Says at Barrons.com
09:58AM  Amgen drug meets goal for those with high genetic cholesterol Reuters
09:31AM  FDA Concerns Are the Least of These Drugs' Worries at Motley Fool
09:21AM  [video] Cramer's Mad Dash: Be careful with Regeneron at CNBC
05:52AM  Regeneron upgraded to Buy from Neutral at Citigroup at theflyonthewall.com
16-Mar-14 07:31PM  Up 755% Over the Past 3 Years, Can This Biotech Be Stopped? at Motley Fool
14-Mar-14 08:00AM  A no-revenue, high-risk tech bet rivaling social Optionetics
08:00AM  A no-revenue, high-risk tech bet rivaling social at CNBC
08:00AM  A no-revenue, high-risk tech bet rivaling social
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company offers EYLEA injection for the treatment of neovascular age-related macular degeneration and macular edema; ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer; and ARCALYST, an injection for subcutaneous use for treating cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its product candidates in clinical development stage comprise EYLEA for the treatment of DME and macular edema ophthalmologic diseases; and ZALTRAP for oncology. The company's antibody-based clinical programs include various human monoclonal antibody product candidates, such as REGN88 for rheumatoid arthritis and non-infectious uveitis; REGN727 for low-density lipoprotein cholesterol reduction; REGN668 for atopic dermatitis, asthma, and nasal polyposis; REGN421, REGN910, and REGN1400 for oncology; REGN475 for the treatment of pain; and REGN1033 for skeletal muscle disorders. It is also developing REGN1154, REGN1154, REGN1193, and REGN1908-1909 antibody product candidates, as well as REGN2176-3, an antibody that is co-formulated with EYLEA for use in ophthalmology. The company distributes its products through Rensselaer facilities and third party service providers. It has strategic collaboration with Sanofi to discover, develop, and commercialize human monoclonal antibodies; and license and collaboration agreement with Bayer HealthCare for the development and commercialization of EYLEA outside the United States. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAKER CHARLES ADirectorMar 24Option Exercise23.8415,000357,60024,000Mar 25 08:03 PM
BAKER CHARLES ADirectorMar 24Sale302.6715,0004,540,0019,000Mar 25 08:03 PM
BROWN MICHAEL SDirectorMar 17Option Exercise33.422,00066,84016,662Mar 18 05:09 PM
BROWN MICHAEL SDirectorMar 17Sale334.292,000668,57314,662Mar 18 05:09 PM
VAGELOS P ROYChairman of the BoardFeb 27Option Exercise12.7070,879899,952140,839Mar 03 09:10 AM
BROWN MICHAEL SDirectorFeb 27Sale335.001,000335,00014,662Feb 27 04:30 PM
BROWN MICHAEL SDirectorFeb 26Option Exercise57.111,00057,11015,662Feb 27 04:30 PM
GOLDSTEIN JOSEPH LDirectorFeb 25Sale338.861,000338,8600Feb 25 05:48 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 25Sale339.5511,8714,030,82363,102Feb 26 04:57 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 24Option Exercise64.9030,2271,961,74685,365Feb 26 04:57 PM
GILMAN ALFRED GDirectorFeb 21Option Exercise18.615,00093,0505,000Feb 24 04:12 PM
SING GEORGE LDirectorFeb 21Option Exercise15.8015,000237,000117,772Feb 24 04:12 PM
GILMAN ALFRED GDirectorFeb 21Sale340.005,0001,700,0000Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 21Sale336.5121,2587,153,60863,102Feb 24 04:11 PM
SING GEORGE LDirectorFeb 21Sale339.0015,0005,085,000112,772Feb 24 04:12 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrFeb 20Option Exercise47.7950,6522,420,80593,102Feb 24 04:11 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 20Option Exercise21.253,00063,7503,000Feb 21 04:43 PM
GOLDSTEIN JOSEPH LDirectorFeb 20Sale326.991,000326,9891,000Feb 21 04:44 PM
Aberman Michael SVP Strategy and Investor RelatFeb 18Sale331.423,6481,209,03615,600Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 18Sale332.6812,8654,279,89320,029Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Option Exercise9.1715,000137,550127,772Feb 19 04:11 PM
Aberman Michael SVP Strategy and Investor RelatFeb 14Option Exercise30.637,500229,72523,100Feb 19 04:12 PM
Terifay Robert JSVP CommercialFeb 14Option Exercise21.2527,795590,64447,824Feb 19 04:10 PM
SING GEORGE LDirectorFeb 14Sale324.0015,0004,860,000112,772Feb 19 04:11 PM
STAHL NEILSVP Research and Development SFeb 13Sale318.8222,6127,209,13624,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Option Exercise89.4515,0001,341,75015,000Feb 13 07:38 PM
STAHL NEILSVP Research and Development SFeb 12Option Exercise20.0654,5481,094,40664,391Feb 13 06:32 PM
SHOOTER ERIC MDirectorFeb 12Sale320.5215,0004,807,8690Feb 13 07:38 PM
GOLDSTEIN JOSEPH LDirectorFeb 12Sale320.621,000320,6202,000Feb 13 04:06 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 12Sale320.3388,98728,504,9851,068,343Feb 13 04:03 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Option Exercise30.635,819178,2365,819Feb 12 04:15 PM
GILMAN ALFRED GDirectorFeb 11Option Exercise18.615,00093,0505,000Feb 12 04:17 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriFeb 11Option Exercise9.49189,4631,798,0041,257,806Feb 13 04:03 PM
GILMAN ALFRED GDirectorFeb 11Sale320.005,0001,600,0000Feb 12 04:17 PM
McCorkle Douglas SVP Controller and Asst TreasurFeb 11Sale325.005,8191,891,1750Feb 12 04:15 PM
VAGELOS P ROYChairman of the BoardFeb 11Sale325.1011,4753,730,523103,275Feb 12 04:15 PM
GILMAN ALFRED GDirectorJan 14Option Exercise18.615,00093,0505,000Jan 14 05:25 PM
GILMAN ALFRED GDirectorJan 14Sale300.005,0001,500,0000Jan 14 05:25 PM
McCorkle Douglas SVP Controller and Asst TreasurJan 14Sale290.004,0001,160,0000Jan 14 05:26 PM
Powchik PeterSVP Clinical Development & RegJan 02Sale274.7720,6685,678,96525,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 31Option Exercise30.6348,0001,470,24073,447Jan 03 04:10 PM
Powchik PeterSVP Clinical Development & RegDec 24Option Exercise21.254,70599,98125,447Dec 26 01:26 PM
Powchik PeterSVP Clinical Development & RegDec 20Sale271.0913336,05520,742Dec 20 05:54 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 19Option Exercise21.254,70599,9811,068,343Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 18Option Exercise21.252956,26921,037Dec 20 05:54 PM
STAHL NEILSVP Research and Development SDec 18Option Exercise21.254,70599,98124,391Dec 19 09:49 PM
GOLDBERG MURRAY ASVP Administration & Asst SecrDec 18Option Exercise21.254,70599,98163,102Dec 19 09:49 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 18Option Exercise21.254,70599,98115,441Dec 19 09:48 PM
Terifay Robert JSVP CommercialDec 18Option Exercise21.254,70599,98120,029Dec 19 09:48 PM
Powchik PeterSVP Clinical Development & RegDec 18Sale270.209,0002,431,80020,742Dec 20 05:54 PM
Powchik PeterSVP Clinical Development & RegDec 17Sale270.0082,16029,742Dec 17 04:16 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise107.1430,6253,281,05638,503Dec 17 04:16 PM
YANCOPOULOS GEORGEPres Regeneron LabsDec 12Option Exercise260.449,5992,499,9641,115,994Dec 13 04:29 PM
VAGELOS P ROYChairman of the BoardDec 02Sale296.119528,1302,257Dec 04 07:34 PM
SING GEORGE LDirectorNov 26Option Exercise15.0110,000150,100122,772Nov 27 04:22 PM
SING GEORGE LDirectorNov 26Sale295.0010,0002,950,000112,772Nov 27 04:22 PM
GOLDSTEIN JOSEPH LDirectorNov 06Sale300.741,000300,7403,000Nov 06 04:17 PM
SCHLEIFER LEONARD SPresident & CEOOct 02Sale313.829,1622,875,25342,087Oct 03 04:14 PM
SCHLEIFER LEONARD SPresident & CEOOct 01Option Exercise111.0129,2763,249,92969,562Oct 03 04:14 PM
BAKER CHARLES ADirectorSep 30Option Exercise19.6915,000295,35024,000Oct 02 04:23 PM
BAKER CHARLES ADirectorSep 30Sale314.0315,0004,710,4399,000Oct 02 04:23 PM
BROWN MICHAEL SDirectorSep 26Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 26Sale309.005,0001,545,00014,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Option Exercise33.425,000167,10019,662Sep 27 04:07 PM
BROWN MICHAEL SDirectorSep 25Sale293.645,0001,468,22214,662Sep 27 04:07 PM
SCHLEIFER LEONARD SPresident & CEOSep 19Sale302.67102,94931,159,18142,087Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Option Exercise16.8015,000252,00035,644Sep 20 04:24 PM
SCHLEIFER LEONARD SPresident & CEOSep 18Option Exercise9.49218,3892,072,512260,476Sep 20 04:25 PM
ROBERTS WILLIAMVP Reg Dev & Med SafetySep 18Sale304.0015,0004,560,00020,644Sep 20 04:24 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 18Sale303.1723,9777,269,04210,736Sep 19 05:16 PM
Van Plew Daniel PSVP & Gen Mgr IOPSSep 17Option Exercise16.8052,500882,00063,236Sep 19 05:16 PM
SCHLEIFER LEONARD SCEO & PresidentSep 09Sale275.475,0001,377,3320Sep 11 04:05 PM
GOLDSTEIN JOSEPH LDirectorAug 23Sale238.291,000238,2904,000Aug 23 05:32 PM
RYAN ARTHUR FDirectorAug 23Sale238.4710,9582,613,15449,855Aug 26 10:26 AM
RYAN ARTHUR FDirectorAug 22Option Exercise31.9030,000956,90062,019Aug 26 10:26 AM
GOLDBERG MURRAY ASVP Finance and Admin CFO andAug 01Option Exercise16.805,00084,00063,554Aug 02 11:37 AM
Aberman Michael SVP Strategy and Investor RelatJun 17Option Exercise24.003,90093,60015,600Jun 18 09:08 AM
BAKER CHARLES ADirectorJun 10Option Exercise15.8015,000237,00024,000Jun 12 09:15 AM
BAKER CHARLES ADirectorJun 10Sale251.8415,0003,777,5479,000Jun 12 09:15 AM
RYAN ARTHUR FDirectorMay 31Sale249.552,500623,88534,855May 31 04:09 PM
GOLDSTEIN JOSEPH LDirectorMay 28Sale252.204,0001,008,8000May 28 04:08 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Option Exercise19.494,02378,396125,389May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 21Sale259.7466,83517,359,65258,554May 22 05:12 PM
GOLDBERG MURRAY ASVP Finance and Admin CFO andMay 20Option Exercise20.02147,9672,962,169135,803May 22 05:12 PM
BROWN MICHAEL SDirectorMay 17Sale269.025,0001,345,12014,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Option Exercise24.4115,000366,15029,662May 17 02:37 PM
BROWN MICHAEL SDirectorMay 15Sale278.2810,0002,782,80019,662May 17 02:37 PM
Aberman Michael SVP Strategy and Investor RelatMay 14Sale279.615,5291,545,96011,700May 15 05:04 PM
Aberman Michael SVP Strategy and Investor RelatMay 13Option Exercise24.0012,500300,00024,200May 15 05:04 PM
STAHL NEILSVP Research and Development SMay 13Sale276.8823,0386,378,80648,988May 14 11:51 AM
SING GEORGE LDirectorMay 10Option Exercise15.015,00075,050117,772May 10 04:19 PM
STAHL NEILSVP Research and Development SMay 10Option Exercise21.9255,4381,215,201104,426May 14 11:51 AM
SING GEORGE LDirectorMay 10Sale270.005,0001,350,000112,772May 10 04:19 PM
Terifay Robert JSVP CommercialMay 08Sale261.238,2312,150,19215,324May 09 04:59 PM
Terifay Robert JSVP CommercialMay 07Option Exercise16.8016,923284,30630,074May 09 04:59 PM
Van Plew Daniel PSVP & General Mgr Industrial OMay 07Sale261.6113,7253,590,63710,736May 08 05:51 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 07Sale262.64100,00026,263,5811,106,395May 08 05:49 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriMay 06Option Exercise13.00192,3082,500,0041,309,638May 08 05:49 PM
Tessier-Lavigne MarcDirectorMay 06Option Exercise53.2313,334709,8348,334May 08 05:52 PM
SHOOTER ERIC MDirectorMay 06Option Exercise37.0920,000741,8005,039May 08 05:53 PM